GHRP-6 Half-Life & Stability
Part of the full GHRP-6 guide - a growth-hormone-releasing peptide reference compound, identity-verified with a COA on every vial.
In brief
Peptide-specific pharmacokinetic constants (a numeric circulating half-life, clearance, or degradation rate) are NOT provided in the source entry for GHRP-6. What the data does support is a structural basis for stability, which is described below alongside general handling principles common to research peptides. General points are explicitly flagged as general rather than GHRP-6-specific.
The detail
A closer look
01
Structural basis for degradation resistance (entry-supported)
The entry states directly that the two D-amino acids in GHRP-6, D-Trp at position 2 and D-Phe at position 5, confer resistance to enzymatic degradation. This is a structure-function property of the molecule: D-configuration residues are poor substrates for proteases that recognize natural L-peptide bonds, so their presence is the documented reason GHRP-6 behaves as a comparatively stable hexapeptide ligand. This is the only stability statement specific to GHRP-6 in the provided data.
02
General peptide-class storage principles (clearly general)
No GHRP-6-specific half-life or shelf-life figure is given, so the following are general laboratory-peptide conventions, not facts from the entry. Lyophilized peptide powder is typically the most stable form and is kept frozen; reconstituted aqueous stocks are less stable and are kept cold and protected from repeated freeze-thaw. Aliquoting before freezing minimizes thaw cycles that degrade peptides over time. These are standard handling practices applied generally and are not derived from any GHRP-6 measurement.
03
What the data does not establish
Because the source does not include in-vitro or in-vivo half-life numbers, no specific circulating duration, degradation half-time, or expiry interval should be inferred for GHRP-6 from this page. Any such value would require data not present in the entry. The honest position supported by the data is qualitative: the D-amino-acid substitutions improve enzymatic stability relative to an all-L analog, full stop.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. GHRP-6 is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.